Ignite Proteomics
Seattle, United States· Est.
A proteomics platform delivering RPPA‑based biomarker assays for oncology decision support and pharma collaborations.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A proteomics platform delivering RPPA‑based biomarker assays for oncology decision support and pharma collaborations.
OncologyImmuno-oncology
Technology Platform
A combined Reverse Phase Protein Array (RPPA) and laser capture microdissection (LCM) workflow that quantifies pathway activation across up to 32 protein biomarkers from tumor tissue.
Opportunities
Expansion of the assay panel to include immune‑checkpoint and metabolic pathways, and pursuit of companion‑diagnostic regulatory approvals could drive significant commercial growth.
Risk Factors
Reliance on antibody validation and competition from emerging proteomics platforms pose technical and market adoption risks.
Competitive Landscape
Ignite differentiates from NanoString and SomaLogic through its integrated LCM‑RPPA workflow and focus on functional pathway activation, but must continuously validate assay robustness to maintain a competitive edge.